Patents Assigned to Nippon Chemiphar Co., Ltd.
-
Publication number: 20240156796Abstract: The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression, the composition containing a selective ?-opioid receptor agonist as an active component, wherein the selective ?-opioid receptor agonist preferably also has a ?-opioid receptor antagonist action and a ?-opioid receptor antagonist action.Type: ApplicationFiled: February 25, 2022Publication date: May 16, 2024Applicants: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, NIPPON CHEMIPHAR CO., LTD.Inventors: Akiyoshi SAITOH, Daisuke YAMADA, Eriko NAKATA
-
Publication number: 20240091362Abstract: There is provided a method for producing a composition containing a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof and having a moisture content of 4.0% by mass or less, the method including irradiating a composition containing a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof with microwaves.Type: ApplicationFiled: March 28, 2022Publication date: March 21, 2024Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hideto TAKEDA, Nozomu SHIMAZAKI
-
Patent number: 11918589Abstract: A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof or a hydrate or solvate thereof as an active ingredient.Type: GrantFiled: April 27, 2017Date of Patent: March 5, 2024Assignees: NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Toshiyasu Imai, Toru Kawasaki, Toru Ogawa, Kazuhide Inoue
-
Publication number: 20230312570Abstract: Provided is a method which is for preparing a morphinan derivative having a diaryl ether skeleton represented by general formula (III) (In the formula, R1 represents a hydrogen atom, etc., R2, R3, and R4 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc., R5 represent a hydrogen atom, a hydroxy group, etc., R14 and R15 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc.), and in which a phenyl group is introduced into the 4-position phenol of a morphinan derivative through the Ullmann reaction of a system using a monovalent copper compound or a novel catalytic system simultaneously using a monovalent copper compound and zero-valent metallic copper.Type: ApplicationFiled: August 27, 2021Publication date: October 5, 2023Applicant: NIPPON CHEMIPHAR CO., LTD.Inventor: Masaaki HIROSE
-
Publication number: 20230248738Abstract: The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.Type: ApplicationFiled: April 17, 2023Publication date: August 10, 2023Applicant: NIPPON CHEMIPHAR CO., LTDInventors: Toshiyasu IMAI, Junzo KAMEI
-
Patent number: 11666582Abstract: The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.Type: GrantFiled: March 14, 2019Date of Patent: June 6, 2023Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Toshiyasu Imai, Junzo Kamei
-
Publication number: 20230159530Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: ApplicationFiled: January 9, 2023Publication date: May 25, 2023Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Publication number: 20230141198Abstract: The present invention provides a compound having a selective opioid ? receptor agonist effect. The present invention provides a pyrazolomorphinan derivative represented by general formula (1) (in the formula, (II) R1 represents a hydrogen atom, an alkyl group, a cycloalkylmethyl group, or the like, R2 represents a hydrogen atom or a hydroxy protecting group, R3 represents a hydroxy group, an alkyl group, a partially unsaturated heterocyclic group, an aryl group, a heteroaryl group, or the like; and R4 represents a hydrogen atom, an alkyl group, an aralkyl group, a cycloalkyl group, a cycloalkyl alkyl group, a saturated heterocyclic group, an aryl group, a heteroaryl group, or the like). The pyrazolomorphinan derivative can be used as an active ingredient in an analgesic, an antidepressant, an anxiolytic, or the like.Type: ApplicationFiled: November 20, 2020Publication date: May 11, 2023Applicants: THE KITASATO INSTITUTE, NIPPON CHEMIPHAR CO., LTD.Inventors: Hideaki FUJII, Shigeto HIRAYAMA, Yoshikazu WATANABE
-
Patent number: 11643411Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: GrantFiled: October 13, 2020Date of Patent: May 9, 2023Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Publication number: 20230132191Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid ? receptor agonist activity.Type: ApplicationFiled: December 15, 2022Publication date: April 27, 2023Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Patent number: 11633392Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor-related diseases (for example, headache) can be treated or prevented.Type: GrantFiled: September 15, 2017Date of Patent: April 25, 2023Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Publication number: 20220380322Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.Type: ApplicationFiled: July 22, 2022Publication date: December 1, 2022Applicant: NIPPON CHEMIPHAR CO., LTDInventors: Masatoshi USHIODA, Kunio KOBAYASHI, Daisuke SAITO, Shogo SAKUMA, Toshiyasu IMAI, Kazuhide INOUE
-
Publication number: 20220323442Abstract: The present invention provides an enteric-coated preparation, including: a compound represented by General Formula (I) wherein R1 is an unsubstituted phenyl group or a phenyl group substituted with a substituent, the substituent being at least one group selected from the group consisting of an alkyl group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with a halogen atom, an alkoxy group having 1 to 8 carbon atoms, an alkoxycarbonyl group having 2 to 8 carbon atoms, a formyl group, a carboxyl group, a halogen atom, a phenyl group and a phenoxy group, R2 is a cyano group or a nitro group, R3 is a hydrogen atom or a hydroxyl group, X is an oxygen atom or —S(O)n—, n is an integer of 0 to 2, and Y is an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 4, 2020Publication date: October 13, 2022Applicants: Nippon Chemiphar Co., Ltd., Nippon Chemiphar Co., Ltd.Inventors: Masuharu Hirano, Takashi Ohta
-
Publication number: 20220289748Abstract: Provided is a method for producing a phenol derivative represented by General Formula (B) and the like, including the step of: allowing metal lithium and liquid ammonia or a primary amine to act on a compound represented by General Formula (A) and the like: wherein Rp1 represents a C6-10 aryl group optionally having a substituent, Rp2 represents a lower alkyl group and the like, and Rq1, Rq2, Rq3, and Rq4 represent a hydrogen atom or any substituent, or adjacent two of Rq1, Rq2, Rq3, and Rq4 optionally form a ring.Type: ApplicationFiled: July 17, 2020Publication date: September 15, 2022Applicant: NIPPON CHEMIPHAR CO., LTD.Inventor: Masaaki HIROSE
-
Patent number: 11434207Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.Type: GrantFiled: March 23, 2020Date of Patent: September 6, 2022Assignee: NIPPON CHEMIPHAR CO., LTDInventors: Masatoshi Ushioda, Kunio Kobayashi, Daisuke Saito, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
-
Publication number: 20220276277Abstract: Provided is a reagent cartridge that can reduce the risk of infection caused by an operator touching a sample or the like during dispensation of the sample or handling of the reagent cartridge, can shorten the test time by improving the work efficiency, and can positively perform analysis of the sample. A reagent cartridge used for an analysis apparatus that analyzes a result based on the reaction of a sample and a reagent includes a sample containing part that contains the sample, a reagent containing part that contains the reagent, and an antibody containing part that contains the antibody, wherein the sample containing part, the reagent containing part, the antibody containing part, and the sample containing part are arranged on the same surface, and the sample containing part includes an injection part and a liquid suction part.Type: ApplicationFiled: July 31, 2020Publication date: September 1, 2022Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Norio TANIMOTO, Kenji UEMURA, Mai EGAMI, Takahiro MATAKI
-
Publication number: 20220267327Abstract: Provided is, for example, a method for producing a morphinan derivative represented by General Formula (II), including the step of: allowing metal sodium and ethylenediamine to act on a morphinan derivative represented by General Formula (I) in presence of an auxiliary solvent. wherein R1 represents a hydrogen atom, or a C1-10 alkyl group, a C3-6 cycloalkyl group, a C2-6 alkenyl group, a C6-10 aryl group, or a heteroaryl group optionally having a substituent, R2 represents an amino protecting group, R3 represents a methoxy group, R4 and R5 represent a hydrogen atom or a hydroxy group, R6 and R7 represent a hydrogen atom or an electron-donating group, wherein R6 and R7 are not simultaneously a hydrogen atom, and X represents O or CH2.Type: ApplicationFiled: July 17, 2020Publication date: August 25, 2022Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Daisuke SAITO, Kohei HAYASHIDA
-
Patent number: 11420944Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a 5-membered heteroaryl group or a fused ring of a 5-membered or 6-membered heterocyclic ring with a benzene ring or a pyridine ring, each of which may have a substituent; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent, or the like; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2.Type: GrantFiled: January 12, 2017Date of Patent: August 23, 2022Assignees: Nippon Chemiphar Co., Ltd., Kinki UniversityInventors: Hiroto Tanaka, Isao Ooi, Yuzo Mogi, Masaaki Hirose, Tsuyoshi Endo, Toru Ogawa, Atsufumi Kawabata
-
Publication number: 20220226299Abstract: A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.Type: ApplicationFiled: March 26, 2020Publication date: July 21, 2022Applicants: NIPPON CHEMIPHAR CO., LTD., UTI LIMITED PARTNERSHIP, KINKI UNIVERSITYInventors: Gerald W. ZAMPONI, Vinicius de Maria GADOTTI, Atsufumi KAWABATA, Toru OGAWA, Hiroto TANAKA, Isao OOI, Daisuke SAITO, Kohei HAYASHIDA, Kohei YAMAMOTO
-
Patent number: 11370761Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydrType: GrantFiled: January 22, 2018Date of Patent: June 28, 2022Assignees: Nippon Chemiphar Co., Ltd., Kinki UniversityInventors: Hiroto Tanaka, Isao Ooi, Kohei Hayashida, Toru Ogawa, Atsufumi Kawabata